SAB Biotherapeutics, Inc. SABS
3.03 USD +0.09 (+3.06%)
At closeNov 6, 2026, 4:01 PM EST
3.03 0.00 0.00%
After hours · Nov 6, 4:01 PM ET
2.91 Day range 3.14
2.49 52-week range 4.59
- YTD
- -18.98%
- 1 year
- -2.26%
News
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock increased by 17.5% to $0.06 during Friday's after-market session. The company's market cap stands at $1.3 million. Nkarta (NASDAQ:NKTX) stock…
benzinga.com SAB Biotherapeutics Q3 2026 Earnings Call Transcript SAB Biotherapeutics (NASDAQ:SABS) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
globenewswire.com SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights Adult and adolescent cohorts fully enrolled in registrational SAFEGUARD study of SAB-142; Pediatric cohort (ages 5–11) actively enrolling with overall enrollment on track for completion in Q4 2026
benzinga.com FDA Provides Fast Track Designation SAB Biotherapeutics' SAB-142 To Treat Stage 3 Type 1 Diabetes SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune…